Protalix BioTherapeutics, Inc. (PLX)
- Previous Close
1.1300 - Open
1.1200 - Bid 1.1400 x 3200
- Ask 1.1300 x 1100
- Day's Range
1.1000 - 1.1660 - 52 Week Range
1.0900 - 3.5500 - Volume
444,946 - Avg. Volume
351,514 - Market Cap (intraday)
84.01M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
12.78 - EPS (TTM)
0.0900 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
www.protalix.comRecent News: PLX
Performance Overview: PLX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLX
Valuation Measures
Market Cap
82.55M
Enterprise Value
64.27M
Trailing P/E
12.56
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.42
Price/Book (mrq)
2.46
Enterprise Value/Revenue
0.98
Enterprise Value/EBITDA
4.97
Financial Highlights
Profitability and Income Statement
Profit Margin
12.69%
Return on Assets (ttm)
9.32%
Return on Equity (ttm)
72.50%
Revenue (ttm)
65.49M
Net Income Avi to Common (ttm)
8.31M
Diluted EPS (ttm)
0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
44.56M
Total Debt/Equity (mrq)
78.29%
Levered Free Cash Flow (ttm)
-1.81M
Research Analysis: PLX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: PLX
Daily – Vickers Top Buyers & Sellers for 10/23/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.